- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01300611
TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation (USBTXA127CBT)
7 décembre 2020 mis à jour par: Tarix Pharmaceuticals
Phase I Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 1-7) to Enhance Engraftment in Adults Undergoing Double Cord Blood Transplantation
The purpose of this study is to evaluate the effect of TXA127 on neutrophil and platelet counts in adult patients who have undergone a double cord blood transplant.
The study will also evaluate the effect of TXA127 on chemotherapy-induced mucositis, an inflammation of the mucous membranes in the digestive tract (mouth to anus) and immune reconstitution which helps patients fight infections.
For patients undergoing CBT, both neutrophil and platelet normalization and immune reconstitution can be delayed.
TXA127 has shown to be well tolerated by patients and appears to induce a rapid production of neutrophils and platelets in the bloodstream as well as increase the immune system components.
It has also been shown to reduce the severity of chemotherapy-induced mucositis.
Aperçu de l'étude
Statut
Résilié
Les conditions
Intervention / Traitement
Description détaillée
Cord blood as a hematopoietic stem cell source has multiple advantages.
Cord blood is normally discarded at birth and can easily be collected and stored.
Availability of numerous CB banks has resulted in genetically diverse CB units including those from non-Caucasians.
Once a suitable CB unit is located, confirmatory typing can be quickly performed and a donor unit can be shipped to the transplant center.
Furthermore, because a CB graft results in a lower incidence of graft-versus-host-disease, one or two antigen-mismatched units are acceptable for transplantation.
Despite these advantages, CB has a significant drawback which is that the number of hematopoietic stem cells obtained from a unit of CB is significantly lower than from a bone marrow (BM) harvest or peripheral blood stem cell (PBSC) harvest.
Both engraftment and immune reconstitution are delayed in patients undergoing CB transplant.
TXA127 is pharmaceutically-formulated angiotensin 1-7, a non-hypertensive derivative of angiotensin II (which contains the 8th amino acid conferring receptor binding to blood pressure receptors).
TXA127 has multilineage effects on hematopoietic progenitors in vitro and in vivo.
The hematopoietic properties demonstrated in preclinical and clinical studies support the investigation of TXA127 to reduce time to neutrophil and platelet engraftment following transfusion of limited number of CD34+ cells.
Type d'étude
Interventionnel
Inscription (Anticipé)
20
Phase
- La phase 1
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- MD Anderson Cancer Center
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans à 60 ans (Adulte)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- Subjects with Acute Myelogenous Leukemia (AML) past first remission, in first or subsequent relapse, induction failure, or in first remission with high-risk for relapse (with high-risk cytogenetics or presence of flt3 mutation or secondary leukemia from prior chemotherapy)
- Myelodysplastic Syndrome or Myelofibrosis of intermediate or high-risk
- Acute Lymphoblastic Leukemia (ALL): Induction failure, fist complete remission with Philadelphia chromosome or translocation (4:11), hypodiploidy and or evidence of minimal residual disease by flow cytometry, second or third complete remission or second relapse
- Chronic Myelocytic leukemia (CML): Second chronic phase or accelerated phase
- Non-Hodgkin's Lymphoma (NHL): Induction failures, second or third complete remission or relapse
- Hodgkin's Lymphoma (HL): Induction failures, second or third complete remission or relapse
- Chronic Lymphocytic leukemia (CLL): Progressive disease following standard therapy
- Other hematologic malignancies which meet investigational site standards for cord blood transplant
- Subjects must be at least 18 years of age
- Subjects must have ECOG status of ≤ 2
- Subjects with bone marrow blasts ≤ 10%
- Subjects must have adequate major organ function
- Male and Female Subjects capable of reproduction must agree to use contraceptive methods during the course of the study and for 2 months following the last administration of study drug
- Cord blood requirements: a) Unrelated CB will be used as a source of hematopoietic support if a 7/8 or 8/8 related or 8/8 unrelated bone marrow donor is not available, or if the tempo of the subject's disease dictates it is not in the subject's best interest to wait for an unrelated marrow donor to be procured. b) Subjects must have two CB units available which are matched with the subject at 4/6, 5/6, or 6/6 HLA class I (serological) and II (molecular) antigens. Each unit must contain at least 1 x 10^7 total nucleated cells/kg recipient body weight (pre-thaw).
Exclusion Criteria:
- Subjects who received antineoplastic treatment including chemotherapy, immunotherapy and radiation therapy ≤ 2 weeks prior to Screening Period
- Subjects who underwent prior total body irradiation
- Subjects who received prior allogeneic hematopoietic cell transplants
- Subjects seropositive for HIV, Hepatitis B or Hepatitis C
- Female subjects who are pregnant or breastfeeding
- Subjects who have received an investigational drug within 30 days of projected first administration of study drug (Day 0)
- Subjects with current alcohol use, illicit drug use, or any other condition (e.g., psychiatric disorder) that, in the opinion of the Investigator, may interfere with the subject's ability to comply with the study requirements or visit schedule
- Subjects with known hypersensitivity to TXA127
- Subjects with uncontrolled medical or psychiatric condition which would limit informed consent
- Subjects with a willing and appropriate HLA-matched related marrow donor
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Non randomisé
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: TXA127 300 mcg/kg/day
Treatment group 1 (300 mcg/kg/day) of a two-arm, dose-escalation pilot feasibility trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect.
|
Injection, 300 mcg/kg/day for 28 days
|
Expérimental: TXA127 1000 mcg/kg/day
Treatment group 2 (1000 mcg/kg/day) of a two-arm, dose-escalation pilot feasibility trial of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation for the treatment of a variety of hematologic malignancies for whom there is no available therapy with substantive anti-disease effect.
|
Injection, 1000 mcg/kg/day for 28 days
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Safety of TXA127 (Angiotensin 1-7) in subjects undergoing double cord blood transplantation
Délai: 100 days post-transplantation
|
The safety and tolerability profile of TXA127 will be provided by descriptively summarizing, at a minimum, the following outcomes: 1) number and proportion of patients with adverse events presented by preferred term, by system organ class (SOC), and by severity grade and relationship to TXA127, as assessed by the Investigator; 2) number and proportion of patients terminating TXA127 due to adverse events related to TXA127; 3) Day 100 treatment-related mortality (TRM) rate; 4) Day 100 mortality rate; 5) number of red blood cell and other blood component transfusions; 6) incidence of infection.
|
100 days post-transplantation
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Reconstitution immunitaire
Délai: 100 jours post-transplantation
|
La reconstitution immunitaire sera évaluée par la mesure des concentrations dans le sang périphérique des cellules CD3+, CD4+, CD8+, CD19+ et CD56+ (réalisée aux jours d'étude 62 et 100).
|
100 jours post-transplantation
|
Incidence, duration, and severity grade of mucositis
Délai: 100 days post-transplantation
|
Incidence of mucositis is defined by the occurrence of least one adverse event with MedDRA preferred term that includes "mucositis" or "stomatitis".
The severity grade will be determined by NCI-CTCAE.
|
100 days post-transplantation
|
Platelet transfusion requirements
Délai: 100 days post-transplantation
|
Platelet transfusion requirements based on units of platelets transfused and days of platelet transfusions
|
100 days post-transplantation
|
Incidence, duration, and severity grade of acute graft-vs-host-disease (aGVHD)
Délai: 100 days post-transplantation
|
Incidence, severity and duration of aGVHD will be reported as a proportion (with 95% CIs) of subjects with Grade II-IV aGVHD.
All incidents of aGVHD will at a minimum be listed, with the severity and time course included.
|
100 days post-transplantation
|
Time to engraftment/recovery
Délai: 100 days post-transplantation
|
Time to neutrophil engraftment and platelet recovery
|
100 days post-transplantation
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Uday R Popat, MD, M.D. Anderson Cancer Center
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 janvier 2011
Achèvement primaire (Réel)
1 décembre 2020
Achèvement de l'étude (Réel)
1 décembre 2020
Dates d'inscription aux études
Première soumission
17 février 2011
Première soumission répondant aux critères de contrôle qualité
17 février 2011
Première publication (Estimation)
21 février 2011
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
8 décembre 2020
Dernière mise à jour soumise répondant aux critères de contrôle qualité
7 décembre 2020
Dernière vérification
1 décembre 2020
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies du système immunitaire
- Tumeurs par type histologique
- Tumeurs
- Troubles lymphoprolifératifs
- Maladies lymphatiques
- Troubles immunoprolifératifs
- Maladies de la moelle osseuse
- Maladies hématologiques
- Troubles myéloprolifératifs
- Leucémie, Lymphoïde
- Leucémie, cellule B
- Lymphome
- Syndromes myélodysplasiques
- Leucémie
- Leucémie myéloïde
- Leucémie, myéloïde, aiguë
- Leucémie-lymphome lymphoblastique à cellules précurseurs
- Leucémie lymphocytaire chronique à cellules B
- Leucémie, myéloïde, chronique, BCR-ABL positif
- Agents antihypertenseurs
- Agents vasodilatateurs
- Angiotensine I (1-7)
Autres numéros d'identification d'étude
- TXA127-2010-001
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur TXA127 300 mcg/kg/day
-
Janssen Pharmaceutical K.K.Complété
-
Mayo ClinicRecrutementUne étude de l'hydromorphone intrathécale pour la réparation de la scoliose idiopathique pédiatriqueContrôle de la douleurÉtats-Unis
-
Cara Therapeutics, Inc.ComplétéPrurit | Prurit urémiqueÉtats-Unis
-
MedImmune LLCComplétéLa leucémie lymphocytaire chronique | Lymphome non hodgkinienÉtats-Unis, Pologne
-
Bausch Health Americas, Inc.ComplétéLa polyarthrite rhumatoïdeÉtats-Unis
-
Eisai Inc.Dr. Reddy's Laboratory; Citius PharmaceuticalsComplétéLymphome T cutané persistant ou récurrentÉtats-Unis, Australie, Porto Rico
-
Protalex, Inc.ComplétéArthrite, rhumatoïdeÉtats-Unis
-
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,The First Affiliated Hospital with Nanjing Medical University; Cancer Institute... et autres collaborateursInconnue
-
Cara Therapeutics, Inc.Complété
-
Cara Therapeutics, Inc.ComplétéPrurit urémiqueÉtats-Unis, Tchéquie, Hongrie, Pologne